Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 17th Preview)
-
Regulatory acceleration: FDA Expedited IND Pilot
The FDA has launched and is accepting applications for an Expedited Investigational New Drug (IND) Pilot aimed at speeding the path to first-in-human studies. The pilot is designed to reduce regulatory friction by partnering drug sponsors with qualified research institutions (QRI) that have established expertise to support efficient IND submissions. The agency says the program will accept applications through Oct. 30, 2026 and reflects “Operation Trialblazer,” a broader initiative to tighten timelines for early clinical development. FDA leadership also said feedback was incorporated into the pilot’s design. For biotech developers, the program could meaningfully shorten the iterative cycle between preclinical packages, manufacturing readiness, and the IND gate—especially for early assets where timing is a competitive differentiator.
-
FDA tightens oversight of foreign clinical trial data
The FDA said it will boost resources for overseas clinical trial facility inspections and update risk-based criteria for selecting foreign sites for audit. Acting CDER director Michael Davis laid out the rationale in a blog post, citing challenges inspecting overseas locations “in the same manner” as domestic sites, including unannounced audits. The agency also flagged capacity and authority gaps in host countries to provide Good Clinical Practice oversight on par with FDA expectations, and it raised concerns about whether “multiregional” trials without meaningful US enrollment can generalize to US patients. For companies running global Phase I and early-stage programs, the change increases the compliance burden for cross-border studies and may affect site selection and trial design strategies.
-
Corporate deal: Novartis buys blood-brain barrier delivery platform from Sironax
Novartis agreed to pay $125 million to acquire a Sironax blood-brain barrier (BBB) crossing technology, securing a platform intended to move multiple modalities into the CNS. The deal hands Novartis global rights to the platform and is expected to support three candidates that Sironax says have “best-in-class” potential. The acquisition comes as Novartis navigates broader R&D pressure, including neuroscience pipeline setbacks. By adding a BBB delivery approach, Novartis is aiming to reduce one of the most persistent constraints in CNS drug development. For CNS-focused biotech and pharma, the transaction underscores that delivery platforms remain high-value assets when clinical data and target biology are present but exposure at the brain interface is the bottleneck.
-
Clinical readout and pipeline milestone: Skyhawk’s RNA-splicing Huntington’s drug
Skyhawk Therapeutics reported extension results for its Huntington’s disease candidate, SKY-0515, describing symptom improvements after 15 months and a continued lowering of mutant huntingtin. On a complex clinical scale, treatment patients averaged a 0.94-point improvement versus a natural-history comparison group that declined by 0.65 points—an absolute gap of 1.59. Skyhawk said the drug was generally well-tolerated with no serious adverse events reported, and at higher doses it reduced mutant huntingtin by more than 60%. The company is now evaluating SKY-0515 across two larger clinical trials, with one completed enrollment. The update reinforces investor and partner interest in RNA-splicing strategies that attempt to tackle underlying disease biology while potentially improving CNS target engagement and tolerability.
-
Cell therapy manufacturing: Cellares and GenomeFrontier scale automated GF-CART01 production
Cellares and GenomeFrontier Therapeutics entered a partnership to evaluate automated manufacturing for GF-CART01 using Cellares’ Cell Shuttle platform. The collaboration focuses on translating GenomeFrontier’s virus-free CAR T manufacturing process to an end-to-end automated electroporation-based workflow. GenomeFrontier is developing GF-CART01 for B-cell malignancies and said it has demonstrated promising clinical data in Taiwan while recruiting for a Phase I trial in the US. The companies framed the partnership as a path to improve manufacturing reliability and scalability for autologous CAR T programs that are still labor-intensive and variable. For CAR T developers, the deal signals continued push toward automation that can reduce cost and throughput constraints while supporting consistent clinical supply.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.